Clinical trials: Atopic Dermatitis Eczema
Skin Dryness
Glyceryl Eicosapentaenoate Based Topic Products as an Irritant-free Cream and Serum for Hydration of Sensitive Skin
This exploratory study aims to verify the hydrating potential as well as the possible irritant effects of a 14-day hydrating treatment consisting of daily application of serum and cream to the skin of two dry targeted areas.
- Trial name
- COS-PBP-01 (NCT06219213)
- Testing
- Glyceryl Eicosapentaenoate serum, Glyceryl Eicosapentaenoate Cream A, Glyceryl Eicosapentaenoate Cream B
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- SCF Pharma
Dermatitis, Atopic, Eczema, Infantile
Goat Infant Formula Feeding and Eczema (the GIraFFE Study)
To determine the relative risk of developing atopic dermatitis in infants fed a study formula based on whole goat milk compared to infants a study formula based on cow milk protein.
- Conditions
- Dermatitis, Atopic, Eczema, Infantile, Infant Development, Child Development
- Trial name
- GIraFFE (NCT04599946)
- Testing
- Infant formula and follow-on formula made from whole goat milk, Infant formula and follow-on formula made from cow's milk ingredients
- Where
- 12 sites in Germany, Poland and 1 more
- Volunteers
- 2,132 people, healthy volunteers welcome
- Sponsor
- Dairy Goat Co-operative (N.Z.) Limited
Dermatitis, Atopic
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis
To assess the efficacy of Locobase REPAIR® when used in children with moderate to severe AD
- Trial name
- NCT00673725
- Testing
- Locobase® REPAIR
- Where
- 3 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Astellas Pharma Europe B.V.
Atopic Dermatitis
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD).
- Trial name
- NCT03585296
- Testing
- ATI-502
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have…
- Trial name
- ECZTRA 7 (NCT03761537)
- Testing
- Tralokinumab
- Where
- 74 sites in Belgium, Czechia and 5 more
- Volunteers
- 277 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
The study will assess the safety and efficacy of QGE031 in the treatment of moderate to severe atopic dermatitis patients. In addition, QGE031 levels in the blood will be measured and the effect of QGE031 on markers in the blood…
- Trial name
- NCT01552629
- Testing
- QGE031, Cyclosporine A
- Where
- 4 sites in Austria, France and 1 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmaceuticals, Ltd) to the Marketed Product…
- Trial name
- NCT02601703
- Testing
- Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%
- Where
- 60 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Atopic Dermatitis (AD)
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD.
- Trial name
- NCT05650320
- Testing
- 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 0% OPA-15406 vehicle
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how…
- Trial name
- ADhope 2 (NCT06526182)
- Testing
- Lebrikizumab
- Where
- 4 sites in Spain
- Volunteers
- 520 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic
Treatment of Atopic Dermatitis by a Full-Body Blue Light Device
Multicentric, placebo-controlled, double-blinded, three-armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2…
- Trial name
- AD-Blue (NCT03085303)
- Testing
- Full Body Blue Light Device
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 87 people
- Sponsor
- Philips Electronics Nederland BV
Atopic Dermatitis
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were < 16 years at the time of first tacrolimus ointment exposure are eligible to…
- Trial name
- APPLES (NCT00475605)
- Where
- 313 sites in United States, Austria and 7 more
- Volunteers
- 8,071 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Effect of Galactooligosaccharides on Incidence of Atopic Manifestations in Infants
Addition of prebiotic galactooligosaccharides to hypoallergenic starter formula would lead to decreased allergic (atopic) symptoms in nonbreastfed infants with a positive history of allergy in family
- Trial name
- NCT02077088
- Testing
- galactooligosaccharide
- Where
- Czechia
- Volunteers
- 120 people
- Sponsor
- Humana Co.Ltd.
Atopic Dermatitis
A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis
This is a study of safety, tolerability, pharmacokinetics and pharmacodynamics of AM1030-CREAM in patients with Atopic Dermatitis.
- Trial name
- NCT02379910
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- AnaMar AB
Atopic Dermatitis, Skin Diseases
Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
This study aims at evaluating the effect of a topical product on the improvement of quality of life and pain of patients suffering from atopic dermatitis or other skin diseases with dryness or severe xerosis.
- Trial name
- NCT05765461
- Where
- 7 sites in Croatia, Germany and 5 more
- Volunteers
- 4,631 people
- Sponsor
- Cosmetique Active International
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Atopic Dermatitis
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD)…
- Trial name
- NCT05034822
- Testing
- Ruxolitinib cream
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT04140695
- Testing
- Tradipitant
- Where
- 51 sites in United States
- Volunteers
- 87 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and…
- Trial name
- ARMADA-AD (NCT07290803)
- Where
- 82 sites in United States, Canada and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Dermatitis, Atopic
Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)
This clinical trial study is two-stage, multi-center, randomized, double-blind, placebo controlled, phase 3 clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis.
- Trial name
- smart(FURIN) (NCT05004324)
- Testing
- FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL
- Where
- South Korea
- Volunteers
- 308 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring.
- Trial name
- NCT05721937
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.